Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety

T lymphocytes expressing a chimeric antigen receptor (CAR) targeting the CD19 antigen (CAR.19) may be of value for the therapy of B-cell malignancies. Because the in vivo survival, expansion and anti-lymphoma activity of CAR.19(+) T cells remain suboptimal even when the CAR contains a CD28 costimula...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoyos, Valentina, Savoldo, Barbara, Quintarelli, Concetta, Mahendravada, Aruna, Zhang, Ming, Vera, Juan, Heslop, Helen E, Rooney, Cliona M., Brenner, Malcolm K, Dotti, Gianpietro
Formato: Texto
Lenguaje:English
Publicado: 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2888148/
https://www.ncbi.nlm.nih.gov/pubmed/20428207
http://dx.doi.org/10.1038/leu.2010.75

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2888148/
https://www.ncbi.nlm.nih.gov/pubmed/20428207
http://dx.doi.org/10.1038/leu.2010.75

Ejemplares similares